Class 4 caution in use-Irbesartan 150mg & 300mg Tablets

Jubilant Pharmaceuticals NV has informed the MHRA that the Patient information leaflet (PIL) in the cartons for the batches listed in this notification include an outdated PIL.

MHRA Drug alert date: 13th January 2025

MHRA Drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-notification-irbesartan-150-mg-and-300-mg-film-coated-tablets-el-25-a-slash-02?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=ba29731f-c857-4e43-9347-5e2d5baeafc8&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please contact: safety.uk@lambda-cro.com, Telephone number: 0080089013370

For stock control enquiries please contact: JPUK.Customerservice@jubl.com, Telephone: +4401233 552293

Class 4 caution in use-Rabeprazole sodium 10 & 20mg GR tablets

Bristol Laboratories Limited has informed the MHRA that the Patient Information Leaflet (PIL) in the batches in the table for Rabeprazole sodium 10mg and 20mg gastro-resistant tablets do not contain the most up to date safety information.

MHRA Drug alert date: 9th January 2025

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-4-medicines-notification-rabeprazole-sodium-10mg-and-20mg-gastro-resistant-tablets-el-25-a-slash-01?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=2ea2f68a-a589-4a59-9548-7c91851e5608&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please contact at: email: info@bristol-labs.co.uk, or telephone: +44 (0) 1442 200 922

For stock control enquiries please contact at email: notifications@bristol-labs.co.uk, or telephone: +44 (0) 1442 200 922

Paula Sutherland Appointed Sales Director at Alliance Healthcare UK

Alliance Healthcare UK is pleased to announce that Paula Sutherland has been appointed to the position of Sales Director. Paula will lead sales teams in delivering products and services to community pharmacies. Her leadership will ensure that Alliance Healthcare offerings align with the unique needs of these pharmacies and, ultimately, the patients they serve.

Paula will lead Alliance Healthcare’s UK sales teams, ensuring that the business’ product offerings align with the unique needs of these pharmacies and, ultimately, the patients they serve.

Paula has been a key figure at Alliance Healthcare since 2012, holding leadership roles that have focused on building strong relationships with community pharmacies, manufacturer partners, and hospital services.

Paula's extensive experience will be instrumental in further strengthening Alliance Healthcare’s partnerships with community pharmacies, which often serve as the first point of contact for patients seeking medical advice and treatment. By leveraging her insights and relationships, she will ensure that our products and services not only meet the demands of the market but also empower pharmacies to thrive as essential health resources in their communities.

Before joining Alliance Healthcare, Paula gained valuable experience in commercial roles within the fast-moving consumer goods sector, at companies such as Perrigo UK and global supply-chain logistics company CHEP.

Paula Sutherland, Sales Director, said: “I am delighted to step into this position at such an exciting time for Alliance Healthcare, and at such a pivotal moment for the sector. Pharmacists play a vital role in local communities up and down the country yet face some of the most challenging circumstances, and I look forward to working closely with our expert field team to listen and enhance our proposition for our pharmacy customers. By ensuring that community pharmacies are well-supported, we can create healthier communities and enhance the quality of care for all patients.”

Marie Evans, Managing Director at Alliance Healthcare said: “Paula has been an invaluable part of the Alliance Healthcare team, demonstrating exceptional leadership and dedication in every role she has undertaken. Pharmacy relationships are an integral part of our business, and Paula’s deep understanding of the pharmacy landscape and ability to foster strong partnerships makes her the ideal person to lead our teams going forwards.”

Class 4 caution in use-Vyvgart 1000mg solution for injection

Argenx BV have informed MHRA that the Patient Information Leaflet (PIL) in the affected packs incorrectly contains reference to two subcutaneous injection sites. Only subcutaneous injection to the abdomen is permitted.

MHRA Drug alert date: 19th December 2024

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-4-medicines-notification-argenx-bv-vyvgart-1000-mg-solution-for-injection-el-24-a-slash-63?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=ab2d5607-6db9-4cc3-9766-16136bc8802d&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please contact ukmedinfo@argenx.com or +44 (0)20 4532 4016.

For stock control enquiries please contact rpi@argenx.com or +44 (0)7801 748936.

Field Safety notice-Various AMS dressings

We have received a field safety notice from Advanced Medical Solutions (AMS) regarding batches of various dressings

Date of recall:17/12/24

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 2 Recall-WockAIR 160 microgram/4.5 microgram, inhalation powder

Wockhardt UK Limited is recalling this batch as a precautionary measure following the identification of a low number of units which may have a defect in the 'top case' resulting in a dose not being able to be dispensed.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-wockhardt-uk-limited-wockair-160-microgram-slash-4-dot-5-microgram-inhalation-powder-el-24-a-slash-62?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=196509da-279d-4663-b40b-c3c0cadad8aa&utm_content=immediately

Further information

For medical information enquiries please telephone 01978 661261 and ask for ‘drug safety’, or email drug.safety@wockhardt.co.uk.

For stock control enquiries please telephone 01978 661261 and ask for ‘customer services’, or email group_uk_csu@wockhardt.co.uk.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited).

Please note that anything not returned to us, or notified to us, within 12 weeks of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-Liothyronine Sodium tablets 5mcg and 20mcg

Strides Pharma UK Ltd has informed MHRA of an error in the patient information leaflet (PIL) for Liothyronine Sodium 20 micrograms Tablets and Liothyronine Sodium 5 micrograms Tablets.

MHRA Drug alert date: 28th November 2024

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-strides-pharma-uk-ltd-liothyronine-sodium-5-and-20-micrograms-tablets-el-24-a-slash-58?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=1b6cc57b-c4b2-4d42-b911-de0ebf43fd1b&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please contact Strides Pharma UK Ltd via email dl-drugsafety@strides.com or telephone +919844460742

For stock control enquiries please contact Strides Pharma UK Ltd via email customerservicesuk@stridespharma.co.uk or telephone 01923 255580

Class 4 caution in use-Oxybutynin hydrochloride Brillpharma 2.5 mg/5 ml Oral Solution

L M Manufacturing Limited has informed the MHRA that the patient information leaflet (PIL) in the cartons for the batch listed for Oxybutynin hydrochloride Brillpharma 2.5 mg/5 ml Oral Solution include an out of date PIL, dated July 2021.

MHRA Drug alert date: 4th December 2024

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-brillpharma-limited-oxybutynin-hydrochloride-brillpharma-2-dot-5-mg-slash-5-ml-oral-solution-el-24-a-slash-61?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=65edb208-204d-4796-8f38-9e6cee8a828f&utm_content=immediately

This is a caution in use only we are not accepting stock returns

For medical information enquiries please contact info@brillpharma.co.uk.

For stock control enquiries please contact Telephone +44 (0) 1582 545500

Class 3 recall-Phenoxymethylpenicillin 250mg/5ml Oral Solution Sugar Free

Kent Pharma UK is recalling a batch of phenoxymethylpenicillin 250mg/5mL oral solution sugar free due to a low phenoxymethylpenicillin assay.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-kent-pharma-uk-phenoxymethylpenicillin-250mg-slash-5ml-oral-solution-sugar-free-el-24-a-slash-60

Further Information

For medical information enquiries please contact medical@kent-athlone.com

For stock control enquiries please contact customer.service@kent-athlone.com

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-Mycophenolate Mofetil 1g / 5ml Oral Suspension

Rosemont Pharmaceuticals Limited has informed the MHRA that the Press-In-Bottle-Adaptor (PIBA) supplied with the batches listed above may cause the medicine to leak when attempting to withdraw a dose.

MHRA Drug alert date: 2nd December 2024

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-rosemont-pharmaceuticals-limited-mycophenolate-mofetil-1g-slash-5ml-oral-suspension-el-24-a-slash-59

This is a caution in use only we are not accepting stock returns

For medical information enquiries please contact pharmacovigilance@rosemontpharma.com, or telephone 0113 244 1400.

For stock control enquiries please contact customerservices@rosemontpharma.com, or telephone 0113 244 1999.